VIENNALAB - Established innovations in diagnostics

Thiopurine-based therapeutic drugs may accumulate to toxic levels in patients carrying genetic variants of the drug-metabolizing enzyme TPMT. The PGX-TPMT StripAssay® identifies the most frequent polymorphisms in the TPMT gene with therapeutic relevance.

Response to Thiopurine-based Therapy

  • Thiopurines are widely used in the treatment of leukemias and autoimmune disorders, and as immunosuppressants after organ transplantation.
  • Thiopurine compounds are converted to therapeutically inactive metabolites by the enzyme thiopurine S-methyltransferase (TPMT) which exists in different isoforms.
  • Some TPMT isoforms have substantially reduced enzyme activity which leads to accumulation of higher thiopurine concentrations when receiving standard dosage. Myelosuppression, a toxic effect on the bone marrow, may thus occur.
  • Identification of a patient's individual TPMT isoform is crucial for avoiding toxic effects of thiopurines.

Product Details

PGX-TPMT StripAssay® ref4-740